NEWS

The invalid oral examination of the patent of Degarek acetate for injection will be conducted at the end of this month.

Release time:

2024-04-03 11:07

 

Degarelix Acetate for Injection(degarelix)It's Huiling Pharmaceutical (Ferring Pharmaceuticals A/S) A class of selective gonadotropin-releasing hormone receptors(GnRHR)Antagonist drugs. It shows significant advantages in the treatment of advanced prostate cancer, which can effectively control the progression of the disease and significantly improve the quality of life of patients. Degarel Acetate for Injection has been2018Approved to enter the Chinese market in,and in2023Enter the National Health Care Negotiation Catalog at the beginning of the year.. According to statistics from public medical institutions in China, the drug is used in2021~2022of the yearUseGrowth rates are respectively8.04%and52.36%.After entering the medical insurance catalogueMoreachieve skyrocketing,Only2023First half of the yearThe useGrowth rateJustUp161.47%.It is a star product with great potential.

The application number of the Chinese patent corresponding to the drug (hereinafter referred to as the patent in question) isCN201380028448.8, its in2017Year9Month8Day Authorization Announcement, with an estimated expiration date2033Year5Month31day. According to the State Intellectual Property Office in2024Year4Month1The case number of the patent involved is4W117479The oral hearing will be held2024Year4Month22At 9: 00 a.m. on the 15th, the invalid claimant was zhengda tianqing pharmaceutical group co., ltd.

Prior to this, Zhengda Tianqing has registered Degarek Acetate for Injection in China, the United States and Europe, and has conducted clinical recruitment for bioequivalence studies in China. According to the information published by China's listed drug patent information registration platform,2024Year1Month23On the 1st, Zhengda Tianqing conducted the injection of Degarek Acetate4Class registration statement. It is reported that Zhengda Tianqing is already in2019Submitted by Degarek Acetate for Injection in4generic listing application,After clinical approval.This timeAlreadySecond submission of generic listing application,The importance attached to the product is evident.

For only the original research drug approved for import, the result of the invalidation will have a significant impact on the market share of the drug. If the patent involved is successfully invalidated, it means that Zhengda Tianqing can advance.9This will undoubtedly bring huge commercial benefits.